0000000000994611

AUTHOR

Lorenzo Lani

showing 1 related works from this author

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

2022

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (…

Atezolizumab-bevacizumabClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCarcinoma HepatocellularSystemic therapyHepatologyHepatocellular carcinomaTirosin-kinase inhibitorLiver NeoplasmsGastroenterologyTirosin-kinase inhibitor.Atezolizumab-bevacizumab; Hepatocellular carcinoma; Systemic therapy; Tirosin-kinase inhibitorBevacizumabFeasibility StudieTyrosineHumanDigestive and Liver Disease
researchProduct